Gut Microbiota in Acute Stroke Patients
Launched by CHINESE UNIVERSITY OF HONG KONG · Apr 30, 2019
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the role of gut bacteria in patients who have suffered an acute ischemic stroke, which is a type of stroke caused by a blockage in the blood vessels supplying the brain. Researchers want to understand how these gut bacteria might affect the patients' recovery and overall health after a stroke. The trial is currently looking for participants aged 18 and older who have been diagnosed with an acute ischemic stroke and have evidence of this condition shown through brain imaging tests like CT or MRI scans.
To participate, individuals must not have any other serious medical conditions that could confuse the results, such as signs of bleeding in the brain or significant gastrointestinal issues. Participants will undergo assessments to help researchers learn more about the connection between gut bacteria and stroke outcomes. This study aims to improve our understanding of stroke recovery and potentially lead to new treatment options in the future. If you or a loved one meet the eligibility criteria and are interested in learning more, please consider reaching out for additional information.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Diagnosed as acute ischaemic stroke
- • 2. Aged 18 or above Chinese
- • 3. Radiological evidence of acute ischaemic stroke by Computed tomography (CT) or magnetic resonance imaging (MRI) brain.
- Exclusion Criteria:
- • 1. Patient with symptoms and signs suggestive of alternative diagnoses,
- • 2. Evidence of intracerebral haemorrhage,
- • 3. Absence of DWI evidence of acute ischaemic infarct,
- • 4. Pregnancy,
- • 5. Evidence of gastrointestinal infection/ inflammation/ obstruction
- • 6. History of partial or total resection of small or large bowel, as well as gut re-anastomosis,
- • 7. Use of antibiotics within 2 weeks prior to symptoms onset,
- • 8. Gastrointestinal malignancy
- • 9. Any hospitalization within 3 months before recruitment
- • 10. Institutionalized patients
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Yiu Ming Bonaventure IP, MRCP
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials